标准治疗无应答丙型肝炎患者的再治疗:重新治疗还是暂时等待?
出处
《肝脏》
2010年第3期206-209,共4页
Chinese Hepatology
基金
国家"十一五"重大科技专项(2008ZX10002-013)
参考文献16
-
1Jensen DM,Marcellin P,Freilich B,et al.Re-treatment of patients with chronic hepatitis C who do not respond to peginterferonalpha2b:a randomized trial.Ann Intern Med,2009,150:528-540.
-
2Jensen DM,Marcellin P,Freilich B,et al.Hepatitis C Nonresponders:Re-treat or Retreat ? Hepatology,2009,50:1307-1309.
-
3Ghany MG,Strader DB,Thomas DL,et al.Diagnosis,management,and treatment of hepatitis C:an update.Hepatology,2009,49:1335-1374.
-
4Kobayashi S,Takeda T,EnomotoM,et al.Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy:a multicenter,retrospective cohort study of 1124 patients.Liver Int,2007,27:186-191.
-
5Poynard T,ColomboM,Bruix J,et al.Peginterferon alfa-2b and ribavirin:effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.Gastroenterology,2009,136:1618-1628.
-
6Cheruvattath R,Rosati MJ,Gautam M,et al.Pegylated interferon and ribavirin failures:is retreatment an option? Dig Dis Sci,2007,52:732-736.
-
7Berg T,Wagner M,Nasser S,et al.Extended treatment duration for hepatitis C virus type:comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.Gastroenterology,2006,130:1086-1097.
-
8S'anchez-Tapias JM,Diago M,Escartin P,et al.Peginterferonalfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.Gastroenterology,2006,131:451-460.
-
9Pearlman BL,Ehleben C,Saifee S.Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.Hepatology,2007,46:1688-1694.
-
10Fried MW,Jensen DM,Rodriguez-Torres M,et al.Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics:randomized study of higher doses of peginterferon alpha-2a and ribavirin.Hepatology,2008,48:1033-1043.
-
1马永红.结核分支杆菌的实验室诊断简述[J].中国临床研究,2013,26(8):842-843. 被引量：1
-
2兰旭青,孟和宝力高,邹丹.C反应蛋白与心血管的关系[J].中国误诊学杂志,2011,11(34):8348-8349.
-
3陈可冀,刘玥.2013ACC／AHA胆固醇治疗指南更新要点解读与思考[J].中国中西医结合杂志,2014,34(2):136-137. 被引量：5
-
4蔡卫民.肝纤维化研究中的若干问题[J].中华肝脏病杂志,2008,16(7):554-557. 被引量：7
-
5田轶伦.间隔支:从解剖到心电图[J].临床心电学杂志,2013,22(2):148-153.
-
6刘萍萍,张健.C反应蛋白与冠状动脉粥样硬化性心脏病[J].心血管病学进展,2007,28(2):212-214. 被引量：14
-
7孙宁玲.2011年高血压领域的回眸[J].中华高血压杂志,2012,20(1):3-5. 被引量：6
-
8张华,曾维政,吴晓玲.红景天干预实验性肝纤维化研究现状[J].世界华人消化杂志,2010,18(25):2666-2672. 被引量：1
-
9张胜本.对功能性便秘诊治的一些意见[J].大肠肛门病外科杂志,2001,7(3):1-2. 被引量：8
-
10Vicky.追踪蛋白埋线减肥[J].医学美学美容,2005(12):108-108.
